Haematology News and Research RSS Feed - Haematology News and Research

Study explores causes of diagnostic delays and impact on treatment in cancer patients

Study explores causes of diagnostic delays and impact on treatment in cancer patients

Patients wait an average of four months before seeking a cancer diagnosis, researchers report at the ESMO ASIA 2016 Congress in Singapore. [More]
Project to help those living with HIV launched by Beckman Coulter

Project to help those living with HIV launched by Beckman Coulter

Beckman Coulter Life Sciences is launching an international HIV/AIDS award at the 2016 conference for the African Society for Laboratory Medicine (ASLM) being held in Cape Town, South Africa (December 3 to 8). [More]
biosurfit announces CE Marking for new HbA1c test

biosurfit announces CE Marking for new HbA1c test

Today, biosurfit SA, the in vitro point-of-care (PoC) diagnostics company, announces CE Marking (Conformité Européenne) for its HbA1c (Haemoglobin A1c) test, the third in a series of tests available on its spinit point-of-care instrument. [More]
World Cancer Congress: DITTA urges development of integrated care approaches in medical technology

World Cancer Congress: DITTA urges development of integrated care approaches in medical technology

In its session at the World Cancer Congress, DITTA, the Global Diagnostic Imaging, Healthcare IT and Radiation Therapy Trade Association explained how fragmentation within healthcare systems makes it difficult for them to effectively manage complex conditions such as cancer where the various dimensions of care - prevention, screening, diagnosis, treatment and palliation – are inseparable. [More]
OGT announces expansion of Cytocell Aquarius Haematology FISH probe range

OGT announces expansion of Cytocell Aquarius Haematology FISH probe range

Oxford Gene Technology, The Molecular Genetics Company, has today announced a significant expansion of its existing catalogue of Cytocell Aquarius Haematology probes for fluorescence in situ hybridisation (FISH) — underlining the company's position as the one-stop-shop for high-quality FISH probes. [More]
Beckman Coulter’s new DxH 500 haematology system installed at University of Chester’s Institute of Medicine

Beckman Coulter’s new DxH 500 haematology system installed at University of Chester’s Institute of Medicine

Beckman Coulter has installed the first DxH 500 haematology analyser in the UK at the University of Chester’s Institute of Medicine on the Countess of Chester Health Park. [More]
Leading experts in iron deficiency to participate in 3rd European Iron Academy meeting

Leading experts in iron deficiency to participate in 3rd European Iron Academy meeting

The 3rd European Iron Academy (EIA) will take place on the 12th and 13th September 2016 in Berlin, Germany, and will bring together over 450 clinicians with an interest in iron deficiency. [More]
NICE MIB offers SD-IORT using Xoft Axxent electronic brachytherapy system for early stage breast cancer patients

NICE MIB offers SD-IORT using Xoft Axxent electronic brachytherapy system for early stage breast cancer patients

NICE (National Institute for Health and Care Excellence) has announced a new Medtech Innovation Briefing (MIB) stating that NHS doctors and commissioners may consider Single Dose Intraoperative Radiotherapy (SD-IORT) using the Xoft Axxent electronic brachytherapy system with ORL managed service as a treatment option for early stage breast cancer patients. [More]
Specialty pharmaceuticals: an interview with David Moran, Clinigen SP

Specialty pharmaceuticals: an interview with David Moran, Clinigen SP

Specialty pharmaceuticals as a category has its origins in the 1970s with complex treatments being developed for disease areas such as cancer, HIV and haemophilia and what characterises a specialty pharmaceutical product is that it will be high touch, high complexity or high cost and is often associated with the treatment of rare or orphan conditions. These products require a considerable amount of expertise, innovation and technology and can be expensive as a result. [More]
Everolimus combined with standard R-CHOP therapy shows promise in treating DLBCL patients

Everolimus combined with standard R-CHOP therapy shows promise in treating DLBCL patients

The targeted therapy everolimus may be safely combined with R-CHOP for new, untreated diffuse large B-cell lymphoma according to the results of a pilot study by Mayo Clinic researchers published in the Lancet Haematology. [More]
Hydroxyurea treatment improves pulmonary function decline in children with sickle cell disease

Hydroxyurea treatment improves pulmonary function decline in children with sickle cell disease

For the first time, researchers were able to demonstrate that children diagnosed with sickle cell disease showed improvement in lung function after treatment with hydroxyurea, a treatment that is underused despite its demonstrated benefits. [More]
Real-world CML management in line with ELN guidelines

Real-world CML management in line with ELN guidelines

The first-line treatment and monitoring of patients with chronic phase-chronic myeloid leukaemia is in accordance with the European LeukaemiaNet recommendations, finds a real-world clinical practice study. [More]
One in 10 people in UK believed to be vitamin B12 deficient

One in 10 people in UK believed to be vitamin B12 deficient

One in 10 people in the UK are believed to be deficient in vitamin B12 – that’s an astonishing six million people suffering from the consequences of having less than the optimum amount of B12 in their system. [More]
CHMP recommends conditional marketing authorisation for Janssen’s daratumumab

CHMP recommends conditional marketing authorisation for Janssen’s daratumumab

Janssen-Cilag announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the granting of a conditional marketing authorisation for first-in-class CD38 immunotherapy daratumumab in the European Union. [More]
Key opinions leaders to discuss role of cyclophosphamide in the field of HSCT

Key opinions leaders to discuss role of cyclophosphamide in the field of HSCT

Key opinions leaders in the field of haematopoetic stem cell transplantation (HSCT) will address the role of Cyclophosphamide, an anti-cancer chemotherapy drug, during the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) that will welcome more than 4,500 delegates in the host city of Valencia, Spain from the 3rd to the 6th of April 2016. [More]
Real-life data show feasibility of imatinib discontinuation in CML

Real-life data show feasibility of imatinib discontinuation in CML

Italian research shows that long-term imatinib discontinuation is feasible outside of a clinical trial setting for patients with chronic myeloid leukaemia who achieve stable undetectable molecular disease with front-line treatment. [More]
Ibrutinib and idelalisib drugs for chronic lymphatic leukaemia can prolong survival time of high-risk patients

Ibrutinib and idelalisib drugs for chronic lymphatic leukaemia can prolong survival time of high-risk patients

Studies conducted at the Comprehensive Cancer Center at MedUni Vienna and Vienna General Hospital show that the drugs ibrutinib and idelalisib used in the targeted treatment of chronic lymphatic leukaemia can significantly prolong the survival time of high-risk patients. [More]
New FDA approval expands use of AstraZeneca's Faslodex for women with HR+, HER2- metastatic breast cancer

New FDA approval expands use of AstraZeneca's Faslodex for women with HR+, HER2- metastatic breast cancer

AstraZeneca today announced that the US Food and Drug Administration has approved a new indication in the US, expanding the use of Faslodex (fulvestrant) to include use in combination with Ibrance (palbociclib). [More]
Potential link between PLCD and ALL could offer new targets for cancer prevention research

Potential link between PLCD and ALL could offer new targets for cancer prevention research

A potential correlation between pre-labor cesarean delivery (PLCD) and acute lymphoblastic leukemia (ALL) could offer new targets for cancer prevention research, according to new research from the Masonic Cancer Center, University of Minnesota. [More]
Lenalidomide trials show potential for expanding lymphoma, leukaemia indications

Lenalidomide trials show potential for expanding lymphoma, leukaemia indications

Positive findings from two clinical trials have been published for the immunomodulatory agent lenalidomide in patients with heavily pretreated mantle cell lymphoma, and in adults with T-cell leukaemia-lymphoma or peripheral T-cell lymphoma. [More]
Advertisement
Advertisement